{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"}],"units":"Participants"}],"description":"According to RECIST v1.1, PD was defined as \\>/=20% relative increase and \\>/=5 mm of absolute increase in the SoD, taking as reference the smallest SoD recorded since treatment started; 1 or more new lesion(s); and/or unequivocal progression of non-target lesions.","groups":[{"description":"Participants received alectinib at a dose of 600 mg via capsule, orally, twice daily, continuously starting on Day 1 Cycle 1 (in 28-day cycles) until PD, death, or withdrawal for any other reasons, whichever occurred first. After PD, participants were allowed to continue treatment with alectinib as per the discretion of the treating physician.","id":"OG000","title":"Alectinib"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on safety population.","reportingStatus":"POSTED","timeFrame":"Baseline; assessments every 8 weeks post-baseline until progressive disease, unacceptable toxicity, consent withdrawal, death, other reason deemed by investigator, or last tumor assessment (up to approximately 2.5 years)","title":"Percentage of Participants With PD as Assessed by IRC According to RECIST v1.1 or Death From Any Cause in Safety Population","type":"SECONDARY","unitOfMeasure":"percentage of participants"}